Phase 2 Study of Venetoclax Plus Carfilzomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma

被引：7

作者：

Costa, Luciano J. ^{[1
]}

Stadtmauer, Edward A. ^{[2
]}

Morgan, Gareth ^{[3
]}

Monohan, Gregory ^{[4
]}

Kovacsovics, Tibor ^{[5
]}

Burwick, Nicholas ^{[6
]}

Jakubowiak, Andrzej ^{[7
]}

Kaufman, Jonathan L. ^{[8
]}

Mobasher, Mehrdad ^{[9
]}

Freise, Kevin J. ^{[10
]}

Ross, Jeremy A. ^{[10
]}

Pesko, John ^{[10
]}

Munasinghe, Wijith ^{[10
]}

Gudipati, Saketh ^{[10
]}

Mudd, Sarah ^{[10
]}

Bueno, Orlando ^{[10
]}

Kumar, Shaji K. ^{[11
]}

机构：

[1] Univ Alabama, Vestavia, AL USA

[2] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA

[3] Univ Arkansas Med Sci, Little Rock, AR 72205 USA

[4] Univ Kentucky, Lexington, KY USA

[5] Univ Utah, Huntsman Canc Inst, Div Hematol & Hematol Malignancies, Salt Lake City, UT USA

[6] VA Puget Sound Hlth Care Syst, Seattle, WA USA

[7] Univ Chicago, Chicago, IL 60637 USA

[8] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA

[9] Genentech Inc, San Francisco, CA USA

[10] AbbVie Inc, N Chicago, IL USA

[11] Mayo Clin, Div Hematol, Rochester, MN USA

来源：

BLOOD | 2018年 / 132卷

关键词：

D O I：

10.1182/blood-2018-99-117026

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

303

引用

页数：3

共 50 条

[21] A phase 1/2 study of carfilzomib in Japanese patients with relapsed and/or refractory multiple myeloma
Watanabe, Takashi
Tobinai, Kensei
Matsumoto, Morio
Suzuki, Kenshi
Sunami, Kazutaka
Ishida, Tadao
Ando, Kiyoshi
Chou, Takaaki
Ozaki, Shuji
Taniwaki, Masafumi
Uike, Naokuni
Shibayama, Hirohiko
Hatake, Kiyohiko
Izutsu, Koji
Ishikawa, Takayuki
Shumiya, Yoshihisa
Kashihara, Tomohisa
Iida, Shinsuke
[J]. BRITISH JOURNAL OF HAEMATOLOGY, 2016, 172 (05) : 745 - 756
[22] Carfilzomib, Pomalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma Patients: A Multicenter, Open Label Phase 1/2 Study
Bringhen, Sara
Oliva, Stefania
Liberati, Anna Marina
Belotti, Angelo
Larocca, Alessandra
Bonello, Francesca
Gaidano, Gianluca
Bertazzoni, Paola
Esma, Fabrizio
Stocchi, Raffaella
Malfitano, Alessandra
Ribolla, Rossella
Di Sano, Chiara
Aschero, Simona
Patriarca, Francesca
De Paoli, Lorenzo
Cafro, Anna Maria
Sonneveld, Pieter
Palumbo, Antonio
Boccadoro, Mario
[J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (01): : E59 - E59
[23] First Analysis from a Phase 1/2 Study of Venetoclax in Combination with Daratumumab and Dexamethasone, plus /-Bortezomib, in Patients with Relapsed/Refractory Multiple Myeloma
Bahlis, Nizar
Baz, Rachid
Harrison, Simon
Quach, Hang
Ho, Shir-Jing
Vangsted, Annette Juul
Moreau, Philippe
Gibbs, Simon
Salem, Ahmed Hamed
Ross, Jeremy A.
Pesko, John
Westrup, Sally
Vue, Jenny
Maciag, Paulo C.
Bueno, Orlando F.
Kaufman, Jonathan L.
[J]. BLOOD, 2019, 134
[24] Venetoclax Combined with Bortezomib and Dexamethasone for Patients with Relapsed/Refractory Multiple Myeloma
Moreau, Philippe
Chanan-Khan, Asher A.
Roberts, Andrew W.
Agarwal, Amit B.
Facon, Thierry
Kumar, Shaji
Touzeau, Cyrille
Cordero, Jaclyn
Ross, Jeremy
Munasinghe, Wijith
Jia, Jia
Salem, Ahmed H.
Leverson, Joel
Maciag, Paulo
Verdugo, Maria
Harrison, Simon J.
[J]. BLOOD, 2016, 128 (22)
[25] A phase one trial of carfilzomib, bendamustine, and dexamethasone in relapsed and/or refractory multiple myeloma
Lee, Hans C.
Feng, Lei
Oriabure, Onyeka
Graham, Vivian
Chen, Wendy
Badillo, Maria
Lu, Rebecca
Lee, Hun J.
Jain, Preetesh
Manasanch, Elisabet E.
Orlowski, Robert Z.
Wang, Michael L.
[J]. AMERICAN JOURNAL OF HEMATOLOGY, 2021, 96 (07) : E243 - E246
[26] Carfilzomib, Elotuzumab and Dexamethasone for Relapsed or Refractory Myeloma Patients
Silvennoinen, Raija Helena
Nahi, Hareth
Anttila, Pekka
Koskenvesa, Perttu
Lievonen, Juha
Marttila, Anu
Varmavuo, Ville
Sikio, Anu
Nurmi, Marita
Saily, Marjaana
Partanen, Anu
Sankelo, Marja
Luoma, Sini
Mantymaa, Pentti
Ilveskero, Sorella
Eshoj, Henrik Rode
Nielsen, Lene Kongsgaard
Jantunen, Esa
Heckman, Caroline A.
[J]. BLOOD, 2020, 136
[27] A phase I study of selinexor combined with weekly carfilzomib and dexamethasone in relapsed/refractory multiple myeloma
Derman, Benjamin A.
Chari, Ajai
Zonder, Jeffrey
Major, Ajay
Stefka, Andrew T.
Jiang, Ken
Karrison, Theodore
Jasielec, Jagoda
Jakubowiak, Andrzej
[J]. EUROPEAN JOURNAL OF HAEMATOLOGY, 2023, 110 (05) : 564 - 570
[28] A Phase II Study of Carfilzomib, Pegylated Liposomal Doxorubicin, and Dexamethasone for Relapsed or Refractory Multiple Myeloma
Fiala, Mark A.
Keller, Jesse
Sekhar, Jeevan
Ceriotti, Connie
Abboud, Camille N.
DiPersio, John F.
Tomasson, Michael H.
Wildes, Tanya M.
Stockerl-Goldstein, Keith
Vij, Ravi
[J]. BLOOD, 2016, 128 (22)
[29] phase II study of daratumumab with weekly carfilzomib, pomalidomide, and dexamethasone in relapsed and refractory multiple myeloma
Yee, Andrew
Nadeem, Omar
Rosenblatt, Jacalyn
Sperling, Adam
Bianchi, Giada
Munshi, Nikhil
O'Donnell, Elizabeth
Branagan, Andrew
Avigan, David
Liegel, Jessica
Harrington, Cynthia
Agyemang, Emerentia
Lively, Kathleen
Packer, Lisette
Han, Samuel
Minsky, Cole
Riadi, Manal
Mcvey, Cailin
Donnelly, Kaleigh
Smith, Caitlin
Katzeff, Mackenna
Goguen, Amy
Horick, Nora
Richardson, Paul
Raje, Noopur
[J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S220 - S221
[30] Phase II Study of Infusional Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma
Lendvai, Nikoletta
Landau, Heather
Lesokhin, Alexander
Tsakos, Ioanna
Koehne, Guenther
Chung, David
Devlin, Sean
Hassoun, Hani
Giralt, Sergio A.
[J]. BLOOD, 2012, 120 (21)

← 1 2 3 4 5 →